Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

23andMe founder and former CEO Anne Wojcicki, interim CEO Joe Selsavage, and William & Mary Law School professor Margaret Hu were called as witnesses to answer questions from committee members.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy.

As part of the court-supervised sale process, 23andMe required all bidders to guarantee that they will comply with its privacy policies and applicable law. Regeneron said that its proposed deal ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy.

Regeneron will be keeping all of 23andMe’s employees, Jensen added. As part of the court-supervised sale process, 23andMe required all bidders to guarantee that they will comply with its privacy ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million. The genetic testing company had filed for bankruptcy protection.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. The proposed transaction ...